Arrowhead’s shot under the skin cut spinal fluid tau by 73%

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Arrowhead says its RNAi drug crossed the blood-brain barrier in healthy volunteers and sharply lowered tau, a protein tied to Alzheimer’s.

The brain guards itself well. A tight barrier of cells lines its blood vessels, and it keeps out most things that float by, including a lot of medicines. That is great for protection and a headache for anyone designing a drug for Alzheimer’s.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 3515

Arrowhead Pharmaceuticals

Longevity level(s):

  • Level 5: Aging disease management
    Therapeutic interventions that manage the symptoms of diagnosed aging diseases (i.e. current mainstream healthcare) and biotechnology companies focused on developing drugs to treat age-related diseases.
  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.

Overview

Arrowhead Pharmaceuticals is a clinical-stage and commercial-stage biopharmaceutical company headquartered in Pasadena, California, focused on developing RNA interference (RNAi) therapeutics to target genes and silence disease-causing pathways. The company leverages its proprietary TRiM™ platform to address therapeutic areas including cardiometabolic diseases (hypertriglyceridemia, cardiovascular disease, obesity), pulmonary conditions (idiopathic pulmonary fibrosis, inflammatory diseases), liver disease, and neuromuscular disorders. Arrowhead's mission centers on translating RNAi science into transformative medicines for patients with previously intractable diseases, with multiple candidates in clinical development and one approved product (plozasiran/REDEMPLO®) for familial chylomicronemia syndrome.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Kyle Umipig

Kyle has nine years of editorial writing experience. They have been following the longevity sector since 2022, focusing on research, emerging tech, and the companies shaping the future of aging and age-related health.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE